Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes

Mori, Yutaka; Kuriyama, Genshin; Tanaka, Takaaki; Tajima, Naoko

doi:10.1007/s12020-009-9235-6

Cited by 8 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 76 weeks, rosuvastatin had significantly decreased LDL‐C by 52.5% ( P < 0.0001) from the baseline value (Figure ). This LDL‐C lowering effect was generally similar to that reported for rosuvastatin in previous studies of statin‐naïve patients . On the other hand, the baseline serum LDL‐C levels in the patients with prior use of lipid‐lowering drugs (n = 92) were above the target (<100 mg/dL) recommended for the secondary prevention of CAD in the JAS2007 guidelines.…”

Section: Resultssupporting

confidence: 86%

“…However, this dose is sometimes too low for patients with a high risk of coronary artery disease (CAD) or refractory hyperlipidemic patients. Therefore, more intensive LDL‐C‐lowering therapy may be necessary .…”

Section: Introductionmentioning

confidence: 99%

“…Indeed, this beneficial effect was obtained with the maximal approved dosage of 20 mg/day for more than 40 weeks in 62% of the patients who completed the study. It is interesting to note that, under these conditions, the decrease in LDL‐C and the increase in high‐density lipoprotein cholesterol (HDL‐C) achieved by rosuvastatin seem to be greater than those achieved with other statins . However, the data are sparse regarding the time‐courses of these effects of rosuvastatin on lipid profiles or its side effects across a wide range of doses.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of Intensive Lipid Lowering on Lipid Profiles Over Time and Tolerability in Stable Coronary Artery Disease: Insights From a Subanalysis of the Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS)

Kawashiri

Yamagishi

Sakamoto

et al. 2013

Cardiovascular Therapeutics

View full text Add to dashboard Cite

SUMMARYBackground: Previous studies have demonstrated that intensive lipid lowering using rosuvastatin results in regression of coronary plaques. However, few data exist regarding lipid profiles over time, drug tolerability, and the effects of prior use of lipid lowering agents in patients on rosuvastatin treatment. Therefore, we studied these matters in a subanalysis of the Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS). Methods: Rosuvastatin was titrated for 76 weeks to attain LDL-C < 80 mg/dL in 213 Japanese dyslipidemic patients with CAD. Clinic visits were scheduled for every 4 weeks during the 76-week study period. Changes over time in lipid parameters, changes in those according to prior lipid-lowering therapy, and changes in those according to baseline lipid levels were evaluated in this subanalysis. Results: Overall, 126 patients completed the study. The mean rosuvastatin dose at the last observation carried forward was 16.9 mg (range, 2.5-20 mg). Rosuvastatin significantly increased HDL-C, lowered LDL-C, and improved the LDL-C/HDL-C ratio (all, P < 0.0001). Increases in serum HDL-C levels were significantly greater in patients with HDL-C < 40 mg/dL than in those with HDL-C ! 40 mg/dL at baseline (P = 0.0005). The estimated glomerular filtration rate increased significantly by 2.84 AE 9.01 mL/min/1.73 m

show abstract

Section: Resultssupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Intensive Lipid Lowering on Lipid Profiles Over Time and Tolerability in Stable Coronary Artery Disease: Insights From a Subanalysis of the Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS)

Kawashiri

Yamagishi

Sakamoto

et al. 2013

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

“…In clinical trials, rosuvastatin achieved marked reductions in serum levels of low density lipoproteins (LDL) cholesterol, accompanied by modest increases in high density lipoproteins (HDL) cholesterol and reductions in triglycerides. [1][2][3] It may also be used in patients with homozygous familial hypercholesterolemia. Rosuvastatin is given orally as the calcium salt, although the doses are expressed in terms of the base.…”

Section: Introductionmentioning

confidence: 99%

Selective Chromatographic Methods for the Determination of Rosuvastatin Calcium in the Presence of Its Acid Degradation Products

Mostafa

Badawey

Lamie

et al. 2014

Journal of Liquid Chromatography & Related Technologies

View full text Add to dashboard Cite

& Two accurate and sensitive stability-indicating methods for the determination of rosuvastatin calcium in the presence of its acid degradation products are presented. The first method utilizes quantitative spectrodensitometric evaluation thin-layer chromatography (TLC) of rosuvastatin calcium in the presence of its acid degradation products, using ethyl acetate=methanol=ammonia (7:3:0.01, by volume) as a mobile phase. Chromatograms are scanned at 245 nm. This method analyzes rosuvastatin calcium in a concentration range of 0.6-3.4 lg=band with mean percentage recovery of 99.78 AE 1.42. The second method is a high-performance liquid chromatography (HPLC) method for the simultaneous determination of rosuvastatin calcium in the presence of its acid degradation products. The mobile phase consists of water=acetonitrile=methanol (40:40:20, by volume). The standard curve of rosuvastatin calcium shows a good linearity over a concentration range of 10-60 lg mL À1 with mean percentage recovery of 100.22 AE 0.86. These methods were successfully applied to the determination of rosuvastatin calcium in bulk powder, laboratory-prepared mixtures containing different percentages of the acid degradation products, and pharmaceutical dosage forms. The validity of results was assessed by applying standard addition technique. The results obtained were found to agree statistically with those obtained by a reported method, showing no significant difference with respect to accuracy and precision.

show abstract

“…6 Statins have been reported to improve hyper-LDL cholesterolaemia and hypertriglyceridaemia, to increase HDL-C, and to reduce the risk for cardiovascular disease in patients with type 2 diabetes and dyslipidaemia. 7 Meta-analyses using the PubMed and LIVALO Õ (pitavastatin) effectiveness and safety (LIVES) Study databases have also shown that various statins can increase HDL-C. 8,9 A statin-induced increase in HDL-C is usually accompanied by a decrease in LDL-C and may be primarily explained by a cholesterol ester transfer protein-mediated mechanism. 8 In addition, there may be different mechanisms involved in the effects of different statins.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia

et al. 2014

View full text Add to dashboard Cite

Objective: To analyse the efficacy of low-dose rosuvastatin for treating hypo high-density lipoprotein (HDL) cholesterolaemia in patients with type 2 diabetes and dyslipidaemia. Methods: Patients with HDL-cholesterol (C) <40 mg/dl and triglycerides (TG) <400 mg/dl who were receiving treatment with lipid-lowering drugs other than rosuvastatin (or previously untreated with lipid-lowering drugs) and with low-density lipoprotein [LDL]-C !120 mg/dl were included. Patients were treated with 2.5 or 5 mg rosuvastatin orally, once daily, to achieve the target LDL-C level specified in Japanese guidelines. Changes in total cholesterol, HDL-C, TG, LDL-C, LDL-C/HDL-C and non-HDL-C at 3 and 6 months were prospectively analysed. Safety was evaluated by examining changes in hepatorenal function, glucose metabolism and creatine kinase. Results: Out of 49 patients, all lipid parameters other than TG were significantly improved at 3 and 6 months. At 3 months, 83.3% of patients had achieved the target LDL-C level. Among nonlipid parameters, no changes were observed except for estimated glomerular filtration rate, which was improved by þ 5.2% and þ 9.6% at 3 and 6 months, respectively. Conclusions: Low-dose rosuvastatin was effective in improving hypo-HDL cholesterolaemia and may have renoprotective effects.

show abstract

Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes

Cited by 8 publications

References 38 publications

Impact of Intensive Lipid Lowering on Lipid Profiles Over Time and Tolerability in Stable Coronary Artery Disease: Insights From a Subanalysis of the Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS)

Impact of Intensive Lipid Lowering on Lipid Profiles Over Time and Tolerability in Stable Coronary Artery Disease: Insights From a Subanalysis of the Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS)

Selective Chromatographic Methods for the Determination of Rosuvastatin Calcium in the Presence of Its Acid Degradation Products

Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia

Contact Info

Product

Resources

About